Jacksonville, FLNCT05789394Now EnrollingIRB Ready

Recurrent Glioblastoma, IDH-Wildtype Clinical Trial in Jacksonville, FL

Access cutting-edge recurrent glioblastoma, idh-wildtype treatment through this clinical trial at a research site in Jacksonville. Study-provided care at no cost to qualified participants.

Sponsored by Mayo Clinic

Quick Self-Assessment

See if you qualify for this Jacksonville location

Preparing your pre-screening questions…

Expert Care in Jacksonville

Access recurrent glioblastoma, idh-wildtype specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related recurrent glioblastoma, idh-wildtype treatment provided free

Apply for This Jacksonville Location

Check if you qualify for this recurrent glioblastoma, idh-wildtype clinical trial in Jacksonville, FL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Jacksonville

    Convenient for FL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Jacksonville site if eligible
  4. 4Begin participation

About This Recurrent Glioblastoma, IDH-Wildtype Study in Jacksonville

This phase I trial tests the safety, side effects, and best dose of allogenic adipose-derived mesenchymal stem cells (AMSCs) in treating patients with glioblastoma or astrocytoma that has come back (recurrent) who are undergoing brain surgery (craniotomy). Glioblastoma is the most common and most aggressive form of primary and malignant tumor of the brain. Currently, the standard of care for this disease includes surgical resection, followed by radiation with chemotherapy and tumor treating fields. Despite this aggressive therapy, the survival after finishing treatment remains low and the disease often reoccurs. Unfortunately, the available therapy options for recurrent glioblastoma are minimal and do not have a great effect on survival. AMSCs are found in body fat and when separated from the fat, are delivered into the surgical cavity at the time of surgery. When in direct contact with tumor cells, AMSCs affect tumor growth, residual tumor cell death, and chemotherapy resistance. The use of AMSCs delivered locally into the surgical cavity of recurrent glioblastoma during a craniotomy could improve the long-term outcomes of these patients by decreasing the progression rate and invasiveness of malignant cells.

Sponsor: Mayo Clinic

Who Can Participate

Inclusion Criteria

Participants \>= 18 years
Karnofsky Performance Scale (KPS) \>= 60
Negative pregnancy test done =\< 7 days prior to registration, for persons of childbearing potential only
Patients with a previous histological diagnosis of glioblastoma multiforme, isocitrate dehydrogenase (IDH) wildtype (WT) or astrocytoma, IDH-mutant World Health Organization (WHO) grade IV according to the 2021 WHO classification of tumors of the central nervous system , who are candidates to- and will undergo a redo craniotomy for excision of recurrent tumor
There is measurable disease according to the immunotherapy response assessment in neuro-oncology (iRANO) criteria
Serum creatinine and urea \<= 2 times the upper limit of normal (=\< 3 weeks prior to registration)
Alanine transaminase (ALT), aspartate transferase (AST) and alkaline phosphatase =\< 3 times the upper limit of normal, and bilirubin =\< 2.5 mg/dL (=\< 3 weeks prior to registration)
Prothrombin time =\< 1.5 times upper limit of normal (=\< 3 weeks prior to registration)
International normalized ratio (INR) and partial thromboplastin time (PTT) =\< 1.5 times the upper limit of normal (=\< 3 weeks prior to registration)
Hemoglobin \>= 9 g/dL (=\< 3 weeks prior to registration)
Platelets \>= 100 x 10\^9/L (=\< 3 weeks prior to registration)
Absolute neutrophil count (ANC) \>= 1.5 x 10\^9/L (=\< 3 weeks prior to registration)
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Patient or legally authorized representative (LAR) is able to fully understand and provide written and verbal consent for the protocol
Willingness to provide mandatory blood specimens for correlative research
Willingness to provide mandatory tissue specimens for correlative research
Willingness to undergo Ommaya reservoir placement and provide cerebrospinal fluid (CSF) samples for correlative research

Exclusion Criteria

Patients who are undergoing needle biopsy only or non-eligible for a surgical intervention
Tumors located solely in the brain stem, midbrain, or thalamus without inclusion/involvement of surrounding brain matter
Previous treatment with bevacizumab
Radiographic evidence of leptomeningeal disease

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Jacksonville?

Yes, this clinical trial (NCT05789394) has an active research site in Jacksonville, FL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Recurrent Glioblastoma, IDH-Wildtype Treatment Options in Jacksonville, FL

If you're searching for recurrent glioblastoma, idh-wildtype treatment options in Jacksonville, FL, this clinical trial (NCT05789394) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Jacksonville research site is actively enrolling participants for this clinical trial. You'll receive care from experienced recurrent glioblastoma, idh-wildtype specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all recurrent glioblastoma, idh-wildtype clinical trials near you to find additional studies recruiting in your area.

More Brain Cancer Trials in Jacksonville, FL

See all brain cancer clinical trials recruiting in Jacksonville — not just this study.

Browse Brain Cancer Trials in Jacksonville →

Browse More Trials by Condition

Brain Cancer TrialsPulmonary Embolism TrialsAnkylosing Spondylitis TrialsInterstitial Lung Disease TrialsAll Conditions →

Ready to Join in Jacksonville?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Jacksonville, FL